318 related articles for article (PubMed ID: 19569180)
21. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
22. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
23. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
24. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
25. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
26. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression.
Khan Z; Tiwari RP; Khan N; Prasad GB; Bisen PS
Curr Gene Ther; 2012 Dec; 12(6):444-53. PubMed ID: 22974420
[TBL] [Abstract][Full Text] [Related]
27. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Hasina R; Hulett K; Bicciato S; Di Bello C; Petruzzelli GJ; Lingen MW
Cancer Res; 2003 Feb; 63(3):555-9. PubMed ID: 12566295
[TBL] [Abstract][Full Text] [Related]
29. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Mandic R; Schamberger CJ; Müller JF; Geyer M; Zhu L; Carey TE; Grénman R; Dünne AA; Werner JA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6845-52. PubMed ID: 16203773
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines.
Ansell A; Jerhammar F; Ceder R; Grafström R; Grénman R; Roberg K
Oral Oncol; 2009 Oct; 45(10):866-71. PubMed ID: 19442568
[TBL] [Abstract][Full Text] [Related]
31. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.
Michna A; Schötz U; Selmansberger M; Zitzelsberger H; Lauber K; Unger K; Hess J
Radiat Oncol; 2016 Jul; 11():94. PubMed ID: 27455841
[TBL] [Abstract][Full Text] [Related]
34. [Up-regulation of human chorionic gonadotropin alpha subunit gene and human mitochondrial cytochrome c oxidase subunit II gene in cis-Diamminedichloroplatinum(II)-resistant human head and neck squamous carcinoma cells].
Higuchi E
Hokkaido Igaku Zasshi; 1999 May; 74(3):231-8. PubMed ID: 10422566
[TBL] [Abstract][Full Text] [Related]
35. Expression of RIPK1 and FADD are associated with chemosensitivity and survival in head and heck squamous cell carcinoma via tanshinone IIA-mediated modulation of the RIPK1-FADD-Caspase 8 complex.
Shen B; Han W; Tan X; Gu KJ; Naseem DF; Zheng G; Li G; Lou J; Chen C
Mol Carcinog; 2024 Jul; 63(7):1406-1416. PubMed ID: 38695620
[TBL] [Abstract][Full Text] [Related]
36. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
[TBL] [Abstract][Full Text] [Related]
37. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
39. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
40. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
